Sumitomo Mitsui Trust Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $29.6M | Buy |
235,488
+4,030
| +2% | +$507K | 0.02% | 585 |
|
|
2025
Q1 | $25.6M | Sell |
231,458
-1,399
| -0.6% | -$155K | 0.02% | 602 |
|
|
2024
Q4 | $31.8M | Buy |
232,857
+916
| +0.4% | +$125K | 0.02% | 569 |
|
|
2024
Q3 | $26.7M | Sell |
231,941
-11,502
| -5% | -$1.33M | 0.02% | 598 |
|
|
2024
Q2 | $33.5M | Sell |
243,443
-9,122
| -4% | -$1.26M | 0.02% | 527 |
|
|
2024
Q1 | $34.8M | Buy |
252,565
+8,630
| +4% | +$1.19M | 0.02% | 592 |
|
|
2023
Q4 | $32.1M | Buy |
243,935
+12,382
| +5% | +$1.63M | 0.02% | 603 |
|
|
2023
Q3 | $26M | Sell |
231,553
-10,951
| -5% | -$1.23M | 0.02% | 627 |
|
|
2023
Q2 | $22.9M | Sell |
242,504
-42,423
| -15% | -$4M | 0.02% | 684 |
|
|
2023
Q1 | $28.8M | Buy |
284,927
+877
| +0.3% | +$88.8K | 0.02% | 639 |
|
|
2022
Q4 | $33.9M | Sell |
284,050
-179
| -0.1% | -$21.4K | 0.03% | 595 |
|
|
2022
Q3 | $30.2M | Buy |
284,229
+1,189
| +0.4% | +$126K | 0.02% | 623 |
|
|
2022
Q2 | $27.6M | Buy |
283,040
+3,122
| +1% | +$304K | 0.02% | 671 |
|
|
2022
Q1 | $26.2M | Sell |
279,918
-15,126
| -5% | -$1.42M | 0.02% | 679 |
|
|
2021
Q4 | $25.1M | Buy |
295,044
+30,585
| +12% | +$2.6M | 0.02% | 684 |
|
|
2021
Q3 | $25.4M | Sell |
264,459
-5,727
| -2% | -$549K | 0.02% | 681 |
|
|
2021
Q2 | $26.3M | Sell |
270,186
-35,100
| -11% | -$3.42M | 0.02% | 690 |
|
|
2021
Q1 | $29.7M | Sell |
305,286
-1,208
| -0.4% | -$117K | 0.02% | 658 |
|
|
2020
Q4 | $29.4M | Sell |
306,494
-32,227
| -10% | -$3.09M | 0.02% | 655 |
|
|
2020
Q3 | $32.6M | Sell |
338,721
-87,124
| -20% | -$8.38M | 0.02% | 600 |
|
|
2020
Q2 | $52M | Sell |
425,845
-127,819
| -23% | -$15.6M | 0.04% | 481 |
|
|
2020
Q1 | $47.9M | Buy |
553,664
+256,002
| +86% | +$22.2M | 0.04% | 449 |
|
|
2019
Q4 | $32M | Buy |
+297,662
| New | +$32M | 0.03% | 603 |
|